This article is part of the Journey to Diagnosis series, produced by Being Patient with support provided by Eli Lilly. Living with multiple sclerosis…
When ancient Greek soldiers laid their mythical siege upon the city of Troy, they struggled to break through the city’s impenetrable walls. To finally…
Years before any symptoms of Alzheimer’s appear, beta-amyloid and tau proteins misfold, tangle, and aggregate inside the brain. While many people may develop beta-amyloid…
Traumatic brain injury is one of the world’s leading cause of death and disability. Blunt force trauma to the brain, often from a bad…
Four people living with cognitive decline share their stories. Below, Being Patient features — in a series of short-form documentary videos — people diagnosed…
Approximately one quarter of hospital beds in acute wards – wards for patients who need close care for a sudden or severe medical conditions…
Treatment with a powerful magnet is one of the newest experimental therapies being used to try to turn back the clock on Alzheimer’s disease….
Before Americans become eligible for Medicare at 65, they often rely on private insurance. But for people who start showing signs of Alzheimer’s in…
Why are researchers still fumbling in the quest to cure what is arguably one of the most important diseases confronting humankind — Alzheimer’s disease?…
Loneliness, heart disease, diabetes, and mental health conditions all put older Americans at a higher risk of developing cognitive decline and Alzheimer’s disease. Looking…
Anti-amyloid drugs like Leqembi and Kisunla are on the market for treating early Alzheimer’s disease, but they are expensive, difficult to access, and only…
For people living with TBI, articulating what is happening inside the brain can be challenging. Daniel Avesar went so far as to get a…
In November of last year, Cassava Sciences announced their experimental Alzheimer’s drug simufilam failed to slow cognitive or functional decline in its 52-week Phase…
European regulators rejected Lilly’s Kisunla citing the number of ARIA-related deaths in its Phase 3 trial. The company will look to appeal the decision….
Our cognition and mental wellbeing are crucial factors for our quality of life and put us in a good position to contribute to society….